Use the search parameters below to filter talks:

Calendar
Calendar

2013 - IXA 2013 Congress (Osaka)

Oral Communication: Clinical(1) Kidney TX
10 November 2013  /  17:15 - 18:20

Outcomes of ABO-Incompatible Living-donor Kidney Transplantation

Presenter: Masashi Takenaka, Tokyo, Japan

- Outcomes of ABO-Incompatible Living-donor Kidney Transplantation

Presenter: Masashi Takenaka, Tokyo, Japan

Oral Communication: Clinical (2)
10 November 2013  /  18:20 - 19:00

Expression of ABO (ABH) histo-blood group antigens in the normal lungs and chimerism in the explanted lungs after ABO incompatible hematopoietic stem cell transplantation.

Presenter: Kyoko Hijiya, , Japan

- Expression of ABO (ABH) histo-blood group antigens in the normal lungs and chimerism in the explanted lungs after ABO incompatible hematopoietic stem cell transplantation.

Presenter: Kyoko Hijiya, , Japan

Long-term evaluation of ABO antibodies after allogeneic ABO incompatible hematopoietic stem cell transplantation

Presenter: Gisella Puga Yung, , Switzerland

- Long-term evaluation of ABO antibodies after allogeneic ABO incompatible hematopoietic stem cell transplantation

Presenter: Gisella Puga Yung, , Switzerland

Early Morning Educational Lecture 1: Differences between anti-HLA Abs and anti-carbohydrate Abs (Main Room)
11 November 2013  /  07:30 - 09:00

The different sensitivity of B cells responding to carbohydrate and HLA antigens to immunosuppressants

Presenter: Hideki Ohdan, Heidelberg, Japan

- The different sensitivity of B cells responding to carbohydrate and HLA antigens to immunosuppressants

Presenter: Hideki Ohdan, Heidelberg, Japan

Anti-HLA Ab

Presenter: Michael Rees, Heidelberg, United States

- Anti-HLA Ab

Presenter: Michael Rees, Heidelberg, United States

Accommodation: Lessen from clinical cases

Presenter: Kazuhide Saito, Heidelberg, Japan

- Accommodation: Lessen from clinical cases

Presenter: Kazuhide Saito, Heidelberg, Japan

Joint Plenary Session: How can we overcome Immune Responses associated with Presensitization? - Optimal Regimen, Accommodation and B-Cell Tolerance
11 November 2013  /  09:30 - 12:30

Current optimal regimens in iABO transplantation

Presenter: Kazunari Tanabe, Boston , Japan

- Current optimal regimens in iABO transplantation

Presenter: Kazunari Tanabe, Boston , Japan

Modification of B-cells in Alloimmunity

Presenter: Stanley Jordan, Boston , United States

- Modification of B-cells in Alloimmunity

Presenter: Stanley Jordan, Boston , United States

Diagnostic challenges in chronic antibody-mediated rejection

Presenter: Robert Colvin, Boston , United States

- Diagnostic challenges in chronic antibody-mediated rejection

Presenter: Robert Colvin, Boston , United States

B cell tolerance

Presenter: Megan Sykes, Boston , United States

- B cell tolerance

Presenter: Megan Sykes, Boston , United States

IXA Plenary Session 1: Update on Preclinical Life-Supporting Organ Xenotransplantation - Current Strategies to Remaining obstacles
11 November 2013  /  13:20 - 15:20

Kidney transplantation

Presenter: Kazuhiko Yamada, Nantes, Japan

- Kidney transplantation

Presenter: Kazuhiko Yamada, Nantes, Japan

Liver transplantation

Presenter: Joseph Tector, Nantes, United States

- Liver transplantation

Presenter: Joseph Tector, Nantes, United States

Lung xenotransplantation

Presenter: Richard N. Pierson III, Nantes, United States

- Lung xenotransplantation

Presenter: Richard N. Pierson III, Nantes, United States

Oral Communication 1: Preclinical Solid Organs
11 November 2013  /  15:40 - 17:10

What progress has been made in pig-to-nonhuman primate transplantation models during the past 15 years? A retrospective review of the literature.

Presenter: David K.C. Cooper, , United States

- What progress has been made in pig-to-nonhuman primate transplantation models during the past 15 years? A retrospective review of the literature.

Presenter: David K.C. Cooper, , United States

Combined CD40-CD154 / CD28-B7 costimulation blockade successfully replaces anti-CD154mAb in preventing a T cell response to genetically-engineered pig artery patch transplants in baboons

Presenter: Hayato Iwase, , United States

- Combined CD40-CD154 / CD28-B7 costimulation blockade successfully replaces anti-CD154mAb in preventing a T cell response to genetically-engineered pig artery patch transplants in baboons

Presenter: Hayato Iwase, , United States

Effect of Systemic Anti-154 (CD40L) Antibody on Clinical Outcomes of Full-thickness Porcine Corneal Graft in Pig-to-Rhesus Corneal Transplantation Model

Presenter: Hyuk Jin Choi, , Korea

- Effect of Systemic Anti-154 (CD40L) Antibody on Clinical Outcomes of Full-thickness Porcine Corneal Graft in Pig-to-Rhesus Corneal Transplantation Model

Presenter: Hyuk Jin Choi, , Korea

In vitro and in vivo testing of an anti-CD40mAb clone, 2C10, in xenotransplantation

Presenter: Hidetaka Hara, , United States

- In vitro and in vivo testing of an anti-CD40mAb clone, 2C10, in xenotransplantation

Presenter: Hidetaka Hara, , United States

Detection of Cytomegalovirus-related gastrointestinal tract lesions in a series of 45 xenotransplanted primates

Presenter: Laura Cavicchioli, , Italy

- Detection of Cytomegalovirus-related gastrointestinal tract lesions in a series of 45 xenotransplanted primates

Presenter: Laura Cavicchioli, , Italy

Advances in a life-supporting xenogenic lung transplant model

Presenter: Lars Burdorf, , United States

- Advances in a life-supporting xenogenic lung transplant model

Presenter: Lars Burdorf, , United States

Over 9 Months Graft Survival Of GTKO.hCD46tg.hTMtg Pig Heterotopic Heart Xenograft In Anti CD40 (2C10) Treated Baboon

Presenter: Muhammad Mohiuddin, , United States

- Over 9 Months Graft Survival Of GTKO.hCD46tg.hTMtg Pig Heterotopic Heart Xenograft In Anti CD40 (2C10) Treated Baboon

Presenter: Muhammad Mohiuddin, , United States

Our Corporate Sponsors

TTS gratefully acknowledges the Corporate Partners whose generous support makes the work of the Society possible:

  • astellas
  • roche
  • sanofi